Factors associated with proviral DNA HIV-1 tropism in antiretroviral therapy-treated patients with fully suppressed plasma HIV viral load: Implications for the clinical use of CCR5 antagonists

Journal of Antimicrobial Chemotherapy

Volumn 65, Issue 4, 2010, Pages 749-751

  Soulié, Cathia ^a,b,c   Fourati, Slim ^a,b,c   Lambert Niclot, Sidonie ^a,b,c   Malet, Isabelle ^a,b   Wirden, Marc ^a,b,c   Tubiana, Roland ^a,b,c   Valantin, Marc Antoine ^a,b,c   Katlama, Christine ^a,b,c   Calvez, Vincent ^a,b,c   Marcelin, Anne Geneviève ^a,b,c  

^a SORBONNE UNIVERSITÉ   (France)

^b INSERM   (France)

^c ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

Author keywords

CCR5 inhibitors; CD4 nadir; DNA tropism; HIV co receptors

Indexed keywords

ANTIRETROVIRUS AGENT; CHEMOKINE RECEPTOR CCR5 ANTAGONIST; VIRUS DNA; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; CHEMOKINE RECEPTOR CCR5; VIRUS RECEPTOR;

AGE; ALGORITHM; ANTIVIRAL SUSCEPTIBILITY; ARTICLE; BLOOD SAMPLING; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; DNA SEQUENCE; FALSE POSITIVE RESULT; GENDER; GENOTYPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; PROVIRUS; TREATMENT DURATION; VIRUS LOAD; CHEMISTRY; DRUG ANTAGONISM; DRUG EFFECT; GENETICS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; ISOLATION AND PURIFICATION; PHYSIOLOGY; VIRAL TROPISM; VIROLOGY;

ANTI-HIV AGENTS; DNA, VIRAL; HIV INFECTIONS; HIV-1; HUMANS; PROVIRUSES; RECEPTORS, CCR5; RECEPTORS, HIV; SEQUENCE ANALYSIS, DNA; VIRAL LOAD; VIRAL TROPISM;

EID: 77952577892     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkq029     Document Type: Article

References (11)

1. Harrigan PR, McGovern R, Dong W et al. Screening for HIV tropism using population based V3 genotyping analysis: a retrospective virological outcome analysis using stored plasma screening samples from MOTIVATE-1. In: Abstracts of the Eighteenth International HIV Drug Resistance Workshop: Basic Principles and Clinical Implications, Fort Myers, FL, USA, 2009. Abstract 15.
2. Soulié C, Tubiana R, Simon A et al. Presence of HIV-1 R5 viruses in cerebrospinal fluid even in patients harboring R5X4/X4 viruses in plasma. J Acquir Immune Defic Syndr 2009; 51:60-4.
3. Moyle GJ, Wildfire A, Mandalia S et al. Epidemiology and predictive factors for chemokine receptor use in HIV-1 infection. J Infect Dis 2005; 191: 866-72.
4. Wilkin TJ, Su Z, Kuritzkes DR et al. HIV type 1 chemokine coreceptor use among antiretroviral-experienced patients screened for a clinical trial of a CCR5 inhibitor: AIDS Clinical Trial Group A5211. Clin Infect Dis 2007; 44: 591-5.
5. Tsibris AM, Kuritzkes DR. Chemokine antagonists as therapeutics: focus on HIV-1. Annu Rev Med 2007; 58: 445-59.
6. Verhofstede C, Vandekerckhove L, Eygen VV et al. CXCR4-using HIV type 1 variants are more commonly found in peripheral blood mononuclear cell DNA than in plasma RNA. J Acquir Immune Defic Syndr 2009; 50: 126-36.
7. Morand-Joubert L, Flandre P, Soulié C et al. Higher detection of CXCR4 tropic virus by genotypic coreceptor analysis in peripheral blood mononuclear cells (PBMC) than in plasma. In: Abstracts of the Seventh European HIV Drug Resistance Workshop, Stockholm, Sweden, 2009. Abstract 51.
8. Frange P, Galimand J, Goujard C et al. High frequency of X4/DM-tropic viruses in PBMC samples from patients with primary HIV-1 subtype-B infection in 1996-2007: the French ANRS CO06 PRIMO Cohort Study. J Antimicrob Chemother 2009; 64: 135-41.
9. Daar ES, Kesler KL, Petropoulos CJ et al. Baseline HIV type 1 coreceptor tropism predicts disease progression. Clin Infect Dis 2007; 45: 643-9.
10. Delobel P, Sandres-Saune K, Cazabat M et al. R5 to X4 switch of the predominant HIV-1 population in cellular reservoirs during effective highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2005; 38: 382-92.
11. Soulié C, Marcelin AG, Ghosn J et al. HIV-1 X4/R5 co-receptor in viral reservoir during suppressive HAART. AIDS 2007; 21: 2243-5.